Currently, PUR0200 is being evaluated for chronic obstructive pulmonary disease (COPD) and the first small molecule formulation from Pulmatrix’s new iSPERSE inhaled dry powder technology.
PUR0200, which contains a long-acting muscarinic agent (LAMA), is being developed as a once-daily therapy in a capsule-based dry powder inhaler (DPI).
The product is being studied for the treatment of COPD and current clinical development is focused on pharmacokinetic bioequivalence in Europe.
Pulmatrix CEO Robert Clarke said: "Our agreement with Mylan for the development of PUR0200 is a major step for Pulmatrix and the continued development of our iSPERSE technology.
"At the current stage of development of PUR0200 and goals of the program, Mylan is the ideal partner to bring this product forward for COPD patients."
As part of the deal, Pulmatrix will lead the development work and pharmacokinetic clinical study with collaborative support from Mylan, which has retained an option for PUR0200 ex-US based on successful completion of the clinical study.